Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.45 -0.3%	$1.40	$1.05 ▼ $5.17	$155.93M	0.38	1.21 million shs	402,410 shs
CPIX Cumberland Pharmaceuticals	$3.15 -7.6%	$4.77	$1.04 ▼ $7.25	$47.13M	-0.39	873,973 shs	120,657 shs
EYEN Eyenovia	$15.96 +51.1%	$3.99	$0.85 ▼ $124.80	$45.97M	2.47	1.26 million shs	4.63 million shs
NLNK NewLink Genetics		$9.07	$0.82 ▼ $3.60	$162.00M	1.17	547,540 shs	N/A
ONCY Oncolytics Biotech	$0.90 +14.4%	$0.55	$0.33 ▼ $1.53	$86.73M	1.07	677,893 shs	1.54 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-1.70%	-7.37%	+3.21%	+25.65%
CPIX Cumberland Pharmaceuticals	0.00%	+21.15%	-41.67%	-25.53%	+105.88%
EYEN Eyenovia	0.00%	+46.69%	+408.28%	+1,562.33%	-74.03%
NLNK NewLink Genetics	0.00%	0.00%	0.00%	0.00%	+97.27%
ONCY Oncolytics Biotech	0.00%	+20.04%	+170.73%	+81.95%	-10.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4299 of 5 stars	3.6	2.0	0.0	0.0	1.9	1.7	0.6
CPIX Cumberland Pharmaceuticals	0.5758 of 5 stars	0.0	3.0	0.0	0.0	2.1	1.7	0.0
EYEN Eyenovia	2.6258 of 5 stars	3.0	5.0	0.0	0.0	3.0	0.0	0.6
NLNK NewLink Genetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	1.6912 of 5 stars	3.4	3.0	0.0	0.0	2.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	572.27% Upside
CPIX Cumberland Pharmaceuticals	0.00	N/A	N/A	N/A
EYEN Eyenovia	2.00	Hold	$2.00	-87.47% Downside
NLNK NewLink Genetics	0.00	N/A	N/A	N/A
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	380.95% Upside

Current Analyst Ratings Breakdown

Latest ONCY, CPIX, EYEN, ACRS, and NLNK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/23/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$17.78M	8.80	N/A	N/A	$1.44 per share	1.00
CPIX Cumberland Pharmaceuticals	$37.87M	1.24	$0.26 per share	12.25	$1.61 per share	1.96
EYEN Eyenovia	$60K	766.08	N/A	N/A	($695.52) per share	-0.02
NLNK NewLink Genetics	$940K	0.00	N/A	N/A	$2.11 per share	0.00
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-732.42%	-30.73%	-22.74%	8/6/2025 (Estimated)
CPIX Cumberland Pharmaceuticals	-$6.48M	-$0.25	N/A	∞	N/A	-7.98%	6.92%	2.33%	8/5/2025 (Estimated)
EYEN Eyenovia	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-316.90%	8/11/2025 (Estimated)
NLNK NewLink Genetics	-$42.99M	-$1.03	N/A	N/A	N/A	-4,592.84%	-41.50%	-33.95%	N/A
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	7/30/2025 (Estimated)

Latest ONCY, CPIX, EYEN, ACRS, and NLNK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	EYEN Eyenovia	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	CPIX Cumberland Pharmaceuticals	N/A	$0.15	N/A	$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EYEN Eyenovia	N/A	N/A	N/A	N/A	N/A
NLNK NewLink Genetics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
CPIX Cumberland Pharmaceuticals	0.18	1.25	1.09
EYEN Eyenovia	N/A	0.34	0.34
NLNK NewLink Genetics	N/A	7.98	7.98
ONCY Oncolytics Biotech	N/A	3.20	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CPIX Cumberland Pharmaceuticals	15.51%
EYEN Eyenovia	25.84%
NLNK NewLink Genetics	32.32%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
CPIX Cumberland Pharmaceuticals	44.85%
EYEN Eyenovia	7.10%
NLNK NewLink Genetics	12.70%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
CPIX Cumberland Pharmaceuticals	80	14.96 million	8.25 million	Optionable
EYEN Eyenovia	40	2.88 million	2.68 million	Optionable
NLNK NewLink Genetics	55	37.33 million	N/A	Not Optionable
ONCY Oncolytics Biotech	30	94.28 million	94.19 million	Not Optionable

ONCY, CPIX, EYEN, ACRS, and NLNK Headlines

Recent News About These Companies

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by Brokerages

July 5 at 4:19 AM | americanbankingnews.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by Analysts

July 5 at 4:14 AM | marketbeat.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages

July 5 at 4:14 AM | marketbeat.com

Oncolytics Biotech (NASDAQ:ONCY) Trading Down 3% - Should You Sell?

July 1, 2025 | marketbeat.com

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

June 30, 2025 | prnewswire.com

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

June 20, 2025 | newswire.ca

Private-Sector Oncology May Be the Market’s Best-Understood Secret

June 20, 2025 | baystreet.ca

USA News Group: With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

June 20, 2025 | finanznachrichten.de

USA News Group: Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

June 18, 2025 | finanznachrichten.de

After Major Oncology Conference, All Eyes Turn to Industry Innovation

June 12, 2025 | prnewswire.co.ukP

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

June 11, 2025 | prnewswire.com

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025 | prnewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunome (IMNM), Oncolytics Biotech (ONCY) and Hookipa Pharma (HOOK)

May 18, 2025 | theglobeandmail.com

Jones Trading Downgrades Oncolytics Biotech (ONCY)

May 17, 2025 | msn.com

Oncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum

May 17, 2025 | finanznachrichten.de

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025 | prnewswire.com

Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14

May 8, 2025 | tipranks.com

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025 | prnewswire.com

Oncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours Trades

May 4, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, CPIX, EYEN, ACRS, and NLNK Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.44 -0.01 (-0.34%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$1.44 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.15 -0.26 (-7.62%)

As of 07/3/2025 03:23 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Eyenovia NASDAQ:EYEN

$15.96 +5.40 (+51.14%)

Closing price 07/2/2025 07:59 PM Eastern

Extended Trading

$15.96 0.00 (0.00%)

As of 07/2/2025 07:59 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

NewLink Genetics NASDAQ:NLNK

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Oncolytics Biotech NASDAQ:ONCY

$0.90 +0.11 (+14.41%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$0.90 +0.00 (+0.44%)

As of 07/3/2025 04:43 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time